Drug Trial Radar · NCT05469854
A Study to Investigate the Pharmacokinetics and ECG Effects of Linaprazan Glurate
Last checked: Nov 20, 2026Latest source record: Jun 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
121
Planned (sponsor's estimate)
Start
Jul 13, 2022
Primary completion
Nov 30, 2026
Study completion Nov 30, 2026
Sponsor
- Lead sponsor
- Cinclus Pharma Holding ABIndustry
- Sponsor type
- Industry
- First posted
- Jul 22, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase I, single-center, double blind, placebo-controlled, parallel-group, randomized trial designed to evaluate the PK, cardiodynamic ECG effects, safety, and tolerability of single oral doses of linaprazan glurate. The trial will explore the PK properties of linaprazan glurate and linaprazan as well as the cardiodynamic ECG effects, safety, and tolerability after the administration of single doses: 300 mg and 600 mg in Part I of the trial, using formulation A of linaprazan glurate, as well as 150 mg, 275 mg, and up to 2 additional dose levels, using formulation C of linaprazan glurate to reach target linaprazan mean Cmax exposure (5222 nmol/L).
Conditions
- Pharmacokinetics
- Cardiodynamic ECG
- Safety, and Tolerability
- GERD
Interventions
Linaprazan glurateDrug
Linaprazan glurate base formulation, 25 mg oral tablets (300 mg and 600 mg doses). Linaprazan glurate hydrochloride (HCl), 25 mg and 50 mg (as base) oral tablets (150 mg, 275 mg and up to 2 additional dose levels).
PlaceboDrug
Single dose, oral tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Measurement of pharmacokinetic profile of linprazan glurate and linaprazan (AUCinf)Time frame: Up to 24 hours
- Measurement of pharmacokinetic profile of linprazan glurate and linaprazan (AUClast)Time frame: Up to 24 hours
- Measurement of pharmacokinetic profile of linprazan glurate and linaprazan (Cmax)Time frame: Up to 24 hours
- Measurement of pharmacokinetic profile of linprazan glurate and linaprazan (T1/2)Time frame: Up to 24 hours
- Measurement of Cardiodynamic ECG (QTcF)Time frame: Up to 24 hours
- Measurement of Cardiodynamic ECG (heart rate)Time frame: Up to 24 hours
- Measurement of Cardiodynamic ECG (PR interval)Time frame: Up to 24 hours
- Measurement of Cardiodynamic ECG (QRS interval)Time frame: Up to 24 hours
- Measurement of Cardiodynamic ECG (placebo-corrected QTcF)Time frame: Up to 24 hours
- Measurement of Cardiodynamic ECG (placebo-corrected heart rate)Time frame: Up to 24 hours
- Measurement of Cardiodynamic ECG (placebo-corrected PR interval)Time frame: Up to 24 hours
- Measurement of Cardiodynamic ECG (placebo-corrected QRS interval)Time frame: Up to 24 hours
- Measurement of Cardiodynamic ECG (categorical outliers)Time frame: Up to 24 hours
- Measurement of Cardiodynamic ECG (changes of T-wave)Time frame: Up to 24 hours
- Measurement of Cardiodynamic ECG (changes of U-wave)Time frame: Up to 24 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CTC Clinical Trial Consultants AB
Uppsala, Sweden · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.